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Background: Monoclonal gammopathies encompass a wide range of diseases characterized by the monoclonal
expansion of a B-cell clone. Despite emerging therapeutic strategies, chances of survival of patients who are affected
are still scarce, which implies that new tools are necessary not only for the diagnosis but also for the follow-up of
patients affected by such diseases. In this context, the use of free light chains (FLCs) has been incorporated into
many guidelines.
Likewise, tumor microenvironment is consistently gaining importance as role player in tumor pathogenesis.
Specifically, Syndecan-1 (CD138), a heparan-sulfate proteoglycan is attracting interests as it is highly expressed
and shed by myeloma plasma-cells.
The aim of our study was to analyze CD138 levels in the serum of patients affected by multiple myeloma or light
chain only disease, and to compare the values obtained with free light chain (FLC) kappa, lambda and FLC ratio
in both groups of patients.
Methods: 84 patients affected by Multiple Myeloma and Light Chain Myeloma were recruited for this study.
Serum CD138 was assessed by ELISA (Diaclone Research, France) and FLC values were quantified by nephelometry
(Freelite TM Human Kappa and Lambda Free Kits, The Binding Site, UK). Data was analyzed by GraphPad Prism software
and Statgraph.
Results: We observed higher CD138 mean values in myeloma patients compared to the light chain only myeloma
group. A positive linear regression of CD138 and FLC was observed in the light chain only cohort as opposed to
myeloma patients which show an inverse trend.
Conclusions: The study highlighted an existing relationship between FLCs and CD138 and wishes to seek also a
correlation in order to rapidly and efficiently perform diagnosis and different diagnostic schemes.
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Monoclonal gammopathies encompass a wide range of
diseases, ranging from Monoclonal Gammopathies of
Uncertain Significance (MGUS) to other M-protein re-
lated disorders, thus representing an increasingly growing
global issue as they account for an elevated amount of
cancers affecting the elderly [1]. They are characterized by* Correspondence: umberto.basile@rm.unicatt.it
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creativecommons.org/publicdomain/zero/1.0/the presence of a Monoclonal Component (MC) produced
by a B-cell clone in expansion. The dysregulated B cell
clone proliferates and secretes either parts or intact immu-
noglobulins (Igs), identifiable in the patient’s serum as a
monoclonal Ig peak by electrophoresis (EF). Most mono-
clonal peaks imply MGUS, which affects approximately
3.5% of the population over 50 years of age with an
average risk of progression to Multiple Myeloma (MM)
or, to a lesser extent, to other lymphoproliferative dis-
orders of 1% per year [2-4]. As the elderly population is
increasing, novel therapies and strategies have greatlyarticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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remains poor, with a 5-year relative survival rate of 35–37%
in newly diagnosed MM patients [5-8].
Consequently, these diseases remain incurable. Despite
asymptomatic emergence, symptoms often intensify as
the disease evolves, substantially reducing health-related
quality of life [9-12]. Monoclonal gammopathies are
often diagnosed secondarily to other investigations,
usually by chance. As population screening is not contem-
plated, early diagnosis plays a major role in uncovering the
underlying disease before it evolves greater malignant
features, since MM is considered to be mostly sensitive
to treatment at diagnosis. Within this context, diagnostic,
monitoring and follow-up tools play a key role in guaran-
teeing an adequate support.
Recently, FLCs have been proposed and accepted as
novel diagnostic and follow-up tools by the global scientific
community, and their use has been incorporated in most
guidelines both at national and international levels [13-20].
Nevertheless, the assays are still lacking an internationally
validated standard, which implies that results are often
discrepant [21,22]. Commercially available FLC assays
represent a major improvement in monoclonal gammo-
pathy detection and monitoring. However, some critical
aspects of both assays still require amelioration, mainly
due to the intrinsic characteristics of FLCs and their el-
evated variability. These, as well as other issues, such as
the elevated ability of FLCs to form dimers, tetramers
and other conformations, cause underestimation from
nonlinear reactions as well as overestimation, possibly
due to a lack of parallelism between antigen and antibody,
as well as to an unknown antigen excess effect [23-26].
It is therefore increasingly important to seek markers
that are indicative of initial malignant proliferation, in
order to achieve differential diagnosis and optimal thera-
peutic indications in the quickest possible manner. In
this light, tumor microenvironment (as well as the role
of exosomes in creating a cancer-fostering niche) has re-
cently led to new strategies and opened up new thera-
peutic scenarios [27].
Of particular interest is the interplay between CD138
and its role in tumor biogenesis. CD138 is a cell surface
transmembrane heparan sulfate proteoglycan expressed
by a variety of cell types. Intact CD138 behaves as cell
signaling mediator at different levels involving different
parts of the molecule [28]. Cell surface CD138 is proc-
essed by a specific heparanase endo-β-D-glucuronidase
consequently releasing the extracellular, bioactive portion
(ectodomain) of the molecule [29]. Normally, CD138 is
constitutively shed at low levels by cells, although the
process is accelerated under specific circumstances and
stimuli, as well as in malignant contexts [30-32]. Elevated
levels of this proteoglycan have been reported in lung can-
cer, Hodgkin’s Lymphoma as well as in MM [33-35].Results from in vitro and in vivo studies suggest a role
of soluble CD138 in promoting tumor growth as well as
tumor cell dissemination. For this reason, the CD138/
heparanase axis is consistently gaining attention as
therapeutic target due to its importance in driving can-
cer and in determining tumor aggressiveness [36,37].
Myeloma cells in the bone marrow, as well as circulating
plasma cells, specifically express high levels of CD138,
thus making them the main source of soluble CD138 in
the context of this disease [38,39]. Shed CD138 may
remain soluble or it may accumulate in the extracellular
matrix [40]. Once shed, CD138 exerts its effects possibly
by fostering the tumor microenvironment by inducing
activation of signaling molecules [41,42]. A limited yet
consistent body of literature reports that serum levels of
CD138 in myeloma patients may be considered an inde-
pendent predictor of poor prognosis for patients [43]
and a reliable prognostic factor at different phases of the
disease [44,45]. In addition, CD138 shedding is also
chemotherapy-induced and a drug-induced relapse of
FLCs has also been observed [46-48]. Moreover, the
same studies reported a notable extramedullary effect of
FLCs following therapy administered to myeloma pa-
tients, pointing to an effect of therapies on tumor
microenvironment. It is therefore of uttermost importance
to consider CD138 interaction with the tumor microenvir-
onment and its effects on the disease prior to drug admin-
istration in myeloma patients.
The aim of our study was therefore to analyze CD138
levels in the serum of patients affected by Intact Immuno-
globulin Multiple Myeloma or Light Chain Multiple Mye-
loma and to compare the values obtained with serum FLC
kappa (κ) or lambda (λ) chains involved in both groups of
myeloma patients. This was done in order to evaluate the
clinical utility of serum levels of CD138 in the differential
diagnosis of monoclonal gammopathies as a parallel bio-
marker to be used in association with the FLC assay, espe-




At the time of the present study, 84 patients (40 women,
44 men, mean age = 63,4 yrs, ±11.6 yrs) affected by MM
and light chain disease were available for analysis and
were recruited in our center at the National Cancer
Institute “Regina Elena” of Rome from 2010 to 2013.
Inclusion criteria were: presence of monoclonal peak by
EF, confirmed by serum immunofixation electrophoresis
(sIFE) as well as urine immunofixation (uIF). Exclusion
criteria included: presence of renal failure, presence of
inflammatory diseases or infections. All subjects were
enrolled in the study during clinical check-ups per-
formed in our center.
Table 2 Distribution of clonality within the Intact
Immunoglobulin Multiple Myeloma cohort
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enrolled. Blood samples were collected once patients
provided their informed consent (in accordance with the
Principles of the Declaration of Helsinki, 6th revision of
Edinburgh, 2000). An aliquot was retained to be tested
for CD138 and all assays were performed in the labora-
tory premises of the Catholic University “A. Gemelli” of
Rome. Patients were then grouped according to the
myeloma type and serum samples were obtained and re-
corded upon performing check-ups, just before therapy.
Patients were then stratified into subgroups, according
to disease type and according to the type of MC at the
time of the first evaluation (either Intact Immunoglobulin
Multiple Myeloma with kappa or lambda light chains or
only Light Chain Multiple Myeloma with either kappa
or lambda light chains, according to the International
Myeloma Working Group Guidelines). Components
were determined by means of serum protein EF, sIF and
uIF. Bone marrow fine needle aspirates were performed
and the diagnosis was assessed according to International
Myeloma Working Group Guidelines. Patient characteris-
tics are reported in Tables 1 and 2.
Control samples were obtained from 40 healthy age-
matched and sex-matched individuals (blood donors).
All controls were previously tested for the presence of
MC by sEF and by both sIFE and uIF (Sebia, France). In-
clusion criteria were: absence of monoclonal peak by EF
and bands on IFE, as well as normal levels of C-Reactive
Protein (CRP). FLC determination on control samples
was omitted, as there would be no light chain involved,
and FLC ratios would fall within normal ranges.
Quantification of CD138s and FLCs
CD138s quantification assay
All samples were assayed at the same time for CD138
and sFLC. Serum CD138 levels were determined using
ELISA kits specific for human CD138 (Diaclone Re-
search, France). The assay was performed according to
the manufacturer’s instructions, as follows: 100 ml of
serum were added to pre-coated wells and incubated
with anti-CD138 biotinylated antibody. The wells were
washed and horseradish peroxidase–streptavidin conju-
gate was added. After washing, the substrate was added,
the reaction was stopped and the absorbance was read at








Females 16 24 40 63 ± 12
Males 18 26 44 62 ± 10
Total 34 50 84 63 ± 11
Age is reported as Mean ± standard deviation.as ng/mL. CD138 levels were measured at least twice for
each patient, with reproducible results. The assay was
performed on the SKYLAB (DASIT, Italy) automatic
system.
FLCs evaluation
Serum FLCs were assessed by means of Turbidimetric
assay (Freelite TM Human Kappa and Lambda Free Kits,
The Binding Site, UK) and performed on the SPAplus
instrument (The Binding Site, UK). Samples were tested
according to the manufacturer’s instructions and serum
dilutions, where necessary, were performed according to
the manufacturer’s recommendations.
Statistical analysis
Collected data sets were reported on Microsoft Excel™
worksheets (Microsoft, Redmond, WA, USA) and analyzed
by Prism GraphPad (La Giolla, CA, USA) and Statgraph.
Graphical interpretation of value distribution was
achieved by plotting Box-and-Whisker plots (in order to
show data distribution of the two pathological cohorts of
patients). Global data distribution was shown by plotting
scatter graphs of the three groups analyzed. Statistical
data analysis was performed using Student’s t-test.
Analysis of linear correlations was performed by
means of Pearson’s correlation, in order to assess the
degree of association of the two variables. Correlation
coefficients are reported in Figure 1. ROC curves (Re-
ceiver Operating Characteristic or Relative Operating
Characteristic curves) were generated by plotting data
(CD138 values of patients against CD138 values of
healthy donors) on GraphPad and the resulting infor-
mation was then re-plotted on Excel (Figure 2). Data
from serum CD138 concentrations in healthy subjects
were plotted against values derived from the two
groups of patients to give estimates of true positive
values (sensitivity) and the proportion of false negatives
(specificity). Plotted values are represented as a curve, and
the Area Under the Curve (AUC) is indicative of diagnos-
tic accuracy. An AUC= 1 (100%) denotes full accuracy of
the test. In this way, it is possible to discriminate normal
from abnormal values, which give an estimate of a cut-off
value for a specific test in a particular setting. Usually, an
Figure 1 Scatter graph and correlations (R) of serum CD138 concentrations versus Serum Free Light Chain Kappa or Lambda concentrations in
Intact Immunoglobulin Multiple Myeloma and Light Chain Myeloma Patients. R values were calculated by Pearson’s correlation.
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deemed statistically significant for P < 0.05.
Results
Samples from the first clinical evaluations were considered:
serum from routine blood tests at initial diagnosis was used
for CD138 and FLC quantifications.
The distribution of serum CD138 concentrations is
depicted in Figure 3a. and b. Box-Plot analysis of data
reveals two different distributions of sCD138 concentra-
tion values among the two pathological groups. Similarly,
a statistically significant difference was observed between
CD138 concentrations of both groups, as depicted in
Figure 3b. As expected, we observed higher serum
CD138 concentrations in the Intact Immunoglobulin
Multiple Myeloma subset of patients compared to Light
Chain Multiple Myeloma patients: mean CD138 values
in Intact Immunoglobulin Multiple Myeloma patients
was 90.7 ng/mL, whereas 40.2 ng/mL in Light Chain
Multiple Myeloma patients (P =0.012). By contrast,
control samples mean CD138 concentration was 15.0 ±
9.0 ng/mL (range = 1-29 ng/mL). Increased sCD138 values
observed within both cohorts of myeloma patients (as op-
posed to the control group) are in line with reports from
other studies [43-45].
Light Chain Multiple Myeloma patients show positive
linear correlation coefficients for sCD138 and involved
FLC, as opposed to Intact Immunoglobulin MultipleMyeloma patients, in which sCD138 levels show a de-
creasing trend when compared to involved FLCs (Figure 1).
Not surprisingly, ROC curves performed for each sub-
group of patients versus sCD138 quantification in controls
were highly significant (P < 0.001). Extrapolated data from
ROC analysis plotted on graphs show that specificity and
sensitivity plots intercept at exactly 75%, for a correspond-
ing sCD138 value of 21.50 ng/mL. 100% sensitivity is first
seen for sCD138 values of 29.50 ng/mL, whereas 100%
specificity corresponds to sCD138 values of 1.5 ng/mL.
On the other hand, Light Chain Multiple Myeloma spe-
cificity and sensitivity plots intercept at sensitivity =
67.5 with a corresponding sCD138 value of 20.5 ng/mL,
and at specificity = 70.59%, which corresponds to sCD138
values of 20.50 ng/mL. 100% sensitivity is seen at sCD138
values = 30.00 ng/mL and specificity at sCD138 values =
9.00 ng/mL. Intact Immunoglobulin Multiple Myeloma
show 95% specificity for sCD138 values = 15.50 ng/mL,
whereas Light Chain Multiple Myeloma 95% specificity is
represented by sCD138 values = 10.00 ng/mL.
Discussion
Our results suggest a possible role of sCD138 as a prog-
nostic marker to be implemented for further use in the
context of monoclonal gammopathies, and in particular
for what concerns MM. A good prognostic system in
MM should ideally form the basis upon which the best
treatment can be selected. It should therefore only include
Figure 2 ROC curves depicting percentage Specificity and Sensitivity of serum CD138 concentration values in Intact Immunoglobulin Multiple
Myeloma versus serum CD138 concentration values in controls, as well as serum CD138 concentration values in Light Chain Multiple Myeloma
versus serum CD138 concentration values in controls.
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In order to be useful within clinical practice, these should
be available at diagnosis and be measured with simple re-
producible techniques. A number of prognostic factors
reflecting various aspects of the disease have been identi-
fied in myeloma, relating to either the intrinsic malignancy
of the tumor, host-tumor interactions, renal function,
or tumor mass. Of these, FLCs concentration is
regarded as one of the most powerful prognostic fac-
tors. In our study, we show that sCD138 provides sub-
stantial prognostic value in a correlation model with
FLCs, considered as valuable prognostic markers. Our
findings uncover an existing relationship between the
FLCs involved and CD138 shedding, and the different
trends in relation to each other.
As depicted in Figure 1, two different correlations
characterize each group of patients when considering
sCD138 against the involved FLCs. Light Chain Mul-
tiple Myeloma shows increasing amounts of sCD138proportionally to a corresponding increase of serum
FLCs. On the contrary, serum of Intact Immunoglobulin
Multiple Myeloma patients shows correspondently lower
levels of CD138 compared to involved FLCs concentration
increase. A stronger trend was generally observed for corre-
lations of FLCs and sCD138 in Light Chain Multiple Mye-
loma (R к/CD138 = 0.47and R λ/CD138 = 0.58) whereas this
was not so evident in the Intact Immunoglobulin Light
Chain Myeloma cohort (R к/CD138 = 0.46 and R λ/CD138 =
0.33). One possible explanation could be due to the
elevated variability of the FLC test, due to the intrinsic
properties of the light chains themselves. This is par-
ticularly true for lambda chains, which are more sus-
ceptible to assay variability due to their properties and
structure. In fact, lambda chains are incline to
polymerization and all commercially available assays
show variability in their detection. Thus, the disper-
sion of values may reflect the intrinsic characteristics
of the FLC.
Figure 3 Distributions of CD138 concentrations a.) Box and Whisker plot depicting the distribution of CD138 serum concentrations in Intact
Immunoglobulin Multiple Myeloma Patients and Light Chain Multiple Myeloma patients. Data in the graph depict the following values: *Intact
Immunoglobulin Multiple Myeloma (Median = 30.5). **Light Chain Multiple Myeloma (Mean = 24.5). b.) Scatter plot depicting CD138 concentrations
among the two groups of patients compared to healthy controls. (Intact Immunoglobulin Multiple Myeloma vs Light Chain Multiple Myeloma
P = 0.012; Intact Immunoglobulin Multiple Myeloma vs Controls P < 0.0001; Light Chain Multiple Myeloma vs Controls P = 0.006). Data in the
graph depict the following values: *Intact Immunoglobulin Multiple Myeloma (Mean = 90.73, SEM = 15.63, SD = 103.80). **Light Chain
Multiple Myeloma (Mean = 40.21, SEM = 9.47, SD = 55.22). ***Controls (Mean = 15, SEM = 1.43, SD = 9.02). (P values were calculated by
Student’s Unpaired t-test).
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order to determine test accuracy, as well as to have an
estimate of the cut-off values for this test. Specificity and
sensitivity of sCD138 in both types of myeloma were
evaluated in order to assess normal and abnormal
values. Specificity at 95% show that sCD138 measure-
ment is capable of detecting Intact Immunoglobulin
Multiple Myeloma for values of sCD138 > 15.5 ng/mL
(Figure 4, Intact Immunoglobulin Multiple Myeloma,
red line plot), whereas Light Chain Multiple Myeloma
are readily detected with a 95% specificity for values of
sCD138 > 10.00 ng/mL (Figure 4, Light Chain Multiple
Myeloma, yellow line plot). These results are possibly
indicative of a differential role played by CD138 shed-
ding and FLCs release in the two pathologies, which
could be exploited as diagnostic marker in order to
achieve a faster and more efficient result. As CD138
shedding has already been signaled as good prognostic
factor in this context [43-45], it is plausible that further
studies may be able to elaborate algorithms by merging
FLC analysis and shed CD138 which may significantlyimprove diagnosis, as well as follow-up and patient
monitoring.
As observed in our study, CD138 shedding varies dif-
ferently according to FLCs released by myeloma cells.
Similarly, myeloma B-cell clones produce a conspicuous
amount of immunoglobulins, which is accompanied by
an altered secretion of FLC as well as by an equivalent
variation of the normal κ/λ ratio, that is at the core of
the FLC quantification assay. Serum FLCs assays rely on
the assumptions that serum concentrations of an unbal-
anced production of FLC in a monoclonal gammopathy
setting yields an altered FLC κ/λ ratio. This is considered
to be a diagnostic aid, especially in those cases in which
the MC is not of great entity. Nevertheless, immuno-
globulin light chains must exit cells in order to circulate
freely: in this context, it is of great interest to consider
the role of CD138 involved in exosome biogenesis, as
these cargo containing vesicles seem to promote cancer
development as well as other pathological conditions
[49]. In light of these findings, it may be appealing to
speculate that the expression and shedding of CD138 as
Figure 4 Data from ROC curve analysis vs CD138 concentrations in Intact Immunoglobulin Multiple Myeloma or Light Chain Multiple Myeloma.
CD138 concentrations corresponding to 95% discrimination specificity of the test are reported within each graph. The black line indicates the
CD138 value corresponding to 95% specificity.
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thermore, their quantification in myeloma patients may not
only be of diagnostic aid, but may also guide towards a
more appropriate therapeutic approach while considering
the physio-pathological effects of both molecules [50,51].
Indeed, MM is characterized by a profoundly altered
equilibrium of factors involved in cell-cell and cell-matrix
interactions, which fosters tumor growth and lytic bone
lesions [52]. Similarly, exosome biogenesis is significantly
up-regulated and exosome protein composition is also
particularly altered within this context [51]. Moreover, as
CD138 seems to be involved in membrane dynamics and
exosome biogenesis, it is of particular interest to explore
the matter in view a significant increase in microvesicleproduction observed in MM and Amyloidosis affected
patients. In addition, the same study reported are routing
process of FLCs via microvesicles and exosomes [53]. In
fact, these structures are often laden with cargo (miRNA,
mRNA, lipids, proteins) possibly represented by tumor-
specific molecules [54]. Several studies have pointed to
the importance of the effects of commonly used
chemotherapy drugs on CD138 shedding [54] as well as
a notable rebound effect of the drugs on FLC production
in these diseases [46; 47]. Therefore, the simultaneous
quantification of these two markers may prove a precious
diagnostic aid and suggest the best therapeutic choice in a
patient-centric manner. Furthermore, as sCD138 itself is
not as variable as FLCs, the quantification of this molecule
Cigliana et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:37 Page 8 of 10could represent a valuable tool to be used alongside with
FLCs quantification during follow-up and monitoring
of myeloma affected subjects undergoing treatments.
This could be done in order to investigate how different
types of myeloma may respond to therapies by shedding
a potential tumor-fostering molecule, thereby limiting
beneficial effects of the drugs. Besides, since both com-
mercially available assays for FLCs quantification are
still lacking standardization and have yet to solve critical
issues due to the enormous intrinsic variability of FLC
molecules themselves (which make them a very unstable
and cumbersome analyte to quantify) it is appealing to
consider implementing FLCs quantification with this
marker as test adjuvant during diagnosis, follow-up and
monitoring of monoclonal gammopathies. Cleaved,
sCD138 is in fact less prone to individual variability as
opposed to FLCs, and this may greatly simplify the de-
tection of this molecule, thus rendering it a more stable
marker to be used alongside standard testing. As it is of
vital importance not to miss out any diagnosis [55],
these two tests could, in the near future, be used as
complementary tools in assisting patient management,
particularly in the context of monoclonal gammopathies.Conclusion
Our study, albeit preliminary, seeks a correlation be-
tween FLCs and soluble CD138. This would enable to
perform diagnosis rapidly and efficiently, especially in
those cases in which the MC is hardly detectable, but
also in consideration of performing different diagnostic
schemes. As it was shown that commonly used chemo-
therapy drugs cause CD138 shedding and that relapse
may often be aggressive and lead to death, it is important
to consider the effects of this molecule. Shed CD138 offers
the advantage of a greater inter-individual antigenic stabil-
ity, as opposed to FLCs which are highly variable and sus-
ceptible to major modifications. It is therefore of absolute
importance, in light of these results, to continue the study
of sCD138 in the context of MGUS patients and to follow
fluctuations of both FLCs and sCD138 in time, so as to
detect the switching point to malignant evolution. Further
studies are needed in order to clarify the clinical utility of
these molecules as markers, and how they may be used
not only for an initial diagnosis but also for differential
diagnosis. Moreover, future perspectives are aimed at
evaluating a possible role for the two analyzed molecules
in precocious disease discrimination before progression.
The different trends observed between the two molecules
may, in the near future, lead to important discriminatory
information regarding what type of MGUS is affecting the
patient but also concerning the evolution of the disease.
Likewise, studies concerning effects of therapy on tumor
microenvironment and on the CD138/heparanase axis aregreatly required in this context, in order to assess benefi-
cial effects of administered drugs.
To conclude, our study highlights the importance of
these molecules and the necessity of pursuing further
studies in order to define the exact role and interplay be-
tween sCD138, exosome cargo and the effects on FLCs in
myeloma, which may reveal to be a key diagnostic marker.
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